• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Granules gets US FDA nod for OTC naproxen sodium and diphenhydramine hydrochloride tablets

expresspharmaSeptember 27, 2020

Tag: granules india , FDA , naproxen sodium , diphenhydramine hydrochloride tablets

Granules India announced that the US Food & Drug Administration (US FDA) has approved its abbreviated new drug application (ANDA) for naproxen sodium and diphenhydramine hydrochloride tablets, 220 mg/25 mg (OTC), generic equivalent of Aleve PM Tablets, 220 mg/25 mg, of Bayer HealthCare.

Naproxen sodium and diphenhydramine hydrochloride tablets are used for relief of occasional sleeplessness associated with minor aches and pains and to help you fall asleep and stay asleep.

Granules now has a total of 31 ANDA approvals from US FDA (29 final approvals and two tentative approvals).

Previous:Dr Reddy’s launches dexmedetomidine hydrochloride in 0.9% sodium chloride injection in US

Next:US FDA approves Zydus Cadila’s dimethyl fumarate DR capsules

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Granules gets US FDA nod for OTC naproxen sodium and diphenhydramine hydrochloride tablets | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Fluorfenicol( FDA)

Fluorfenicol( FDA)
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
HFHA(m-6FDAP)

HFHA(m-6FDAP)
Naproxen sodium

Naproxen sodium
Simvastatin (FDA)

Simvastatin (FDA)
Prednisolone (FDA /COS)

Prednisolone (FDA /COS)
Naproxen Sodium

Naproxen Sodium
Gemfibrozil (FDA)

Gemfibrozil (FDA)
Tobramycin base( FDA)

Tobramycin base( FDA)
Deltamine (FDA)

Deltamine (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service